RxDoctor Payments Data

Xanthe Victoria, MD

Family Medicine · Bellflower, CANPI 1447270418

Payments from drug & device makers

$1,129in general payments, 2019–2025

Across 31 payments — averaging $36.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$187
  • Novo Nordisk$182
  • Otsuka America Pharmaceutical, Inc.$177
  • AstraZeneca$128
  • Alkermes, Inc.$81
  • Boehringer Ingelheim$74
  • plus $301 from 9 others

What the payments were for

  • Food & beverage$1,03091%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,129 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$358,155
Medicare patients
349
Services billed
3,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate56$259,664
Invega SustennaPaliperidone Palmitate76$256,849
TradjentaLinagliptin442$133,373
EliquisApixaban351$118,191
NuplazidPimavanserin Tartrate28$100,403
RexultiBrexpiprazole74$75,916
JanuviaSitagliptin Phosphate141$57,512
ProcritEpoetin Alfa34$48,570
JardianceEmpagliflozin84$37,011
Divalproex Sodium340$31,743
CreonLipase/Protease/Amylase22$29,216
XareltoRivaroxaban57$25,003
RybelsusSemaglutide17$20,805
LokelmaSodium Zirconium Cyclosilicate41$17,886
XifaxanRifaximin11$17,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Procrit, Xarelto$12$330,422167 claims
Boehringer IngelheimTradjenta, Jardiance$74$170,384526 claims
Otsuka America Pharmaceutical, Inc.Rexulti$177$75,91674 claims
Novo NordiskRybelsus, Ozempic$182$33,52130 claims
AstraZenecaLokelma, Farxiga, Symbicort$128$30,98379 claims
Sunovion Pharmaceuticals Inc.Aptiom$23$17,22724 claims
NovartisEntresto$25$14,74451 claims
Lilly USA, LLCOlanzapine$48$7,583231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Bellflower

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →